Table 6

Indirect comparison results: duloxetine vs. gabapentin.

Outcome

Indirect treatment comparison (δ)

Mean (median)

95% CI for δ

Between-study variance (τ 2)

Mean (median)

95% CI for τ2


Efficacy

Reduction in 24-hour pain intensity

0.270 (0.266)

(-0.469; 1.022)

0.041 (0.013)

(0.001; 0.247)


Tolerability

Premature study discontinuation due to:

- Lack of efficacy

0.067 (0.065)

(-1.988; 2.116)

0.177 (0.028)

(0.001; 1.281)

- Adverse events

0.841 (0.835)

(-0.348; 2.065)

0.062 (0.015)

(0.001; 0.406)

- Other

-0.245 (-0.252)

(-1.527; 1.075)

0.060 (0.015)

(0.001; 0.386)

Diarrhoea

-0.244 (-0.246)

(-1.645; 1.164)

0.273 (0.051)

(0.001; 1.825)

Dizziness

-1.044 (-1.054)

(-2.258; 0.183)

0.090 (0.021)

(0.001; 0.590)

Headache

-0.689 (-0.697)

(-1.986; 0.638)

0.053 (0.013)

(0.001; 0.348)

Nausea

0.704 (0.700)

(-0.567; 2.021)

0.085 (0.022)

(0.001; 0.529)

Somnolence

-0.101 (-0.107)

(-1.249; 1.078)

0.080 (0.016)

(0.001; 0.545)


Note:

δ is the mean difference in treatment effect between DLX and each comparator.

τ2 is between-study heterogeneity.

Quilici et al. BMC Neurology 2009 9:6   doi:10.1186/1471-2377-9-6

Open Data